Journal de Pharmacie de Belgique - 101ème année n° 1 - mars 2019 35
5 Carrillo-Muñoz AJ, Quindós G,
Tur C, et al. In-vitro antifungal
activity of liposomal nystatin
in comparison with nystatin,
amphotericin B cholesteryl
sulphate, liposomal
amphotericin B, amphotericin B
lipid complex, amphotericin B
desoxycholate, fluconazole
and itraconazole. J Antimicrob
Chemother 1999;44:397-401.
6 Gunderson SM, Hoffman H,
Ernst EJ, et al. In vitro
pharmacodynamic characteristics
of nystatin including timekill
and postantifungal effect.
Antimicrob Agents Chemother
2000;44:2887-90.
7 Ghannoum MA, Rice LB.
Antifungal Agents : Mode of
Action, Mechanisms of Resistance,
and Correlation of These
Mechanisms with Bacterial
Resistance. 1999;12:501-17.
8 Samaranayake LP,
Keung Leung W, Jin L. Oral
mucosal fungal infections.
Periodontolo 2000 2009;49:39-59.
9 Micromedex. Disponible en ligne:
www.micromedexsolutions.com/
(consulté en juin 2018).
10 Liu W, Guan X, Yu Z, et al. A
Drug-drug Interaction Between
Cyclosporine and Nystatin. Clin
Ther 2018;40:660–2.
11 U S Food and Drug Administration.
Disponible en ligne : www.fda.gov/
(consulté en juin 2018).
12 Niimi M, Firth NA, Cannon RD.
Antifungal drug resistance of oral
fungi. Odontology 2010;98:15-25.
13 Cannon RD, Chaffin WL.
Oral Colonization by Candida
Albicans. Crit Rev Oral Biol Med
1999;10(3):359-83.
14 Pappas PG, Kauffman CA,
Andes DR, et al. Clinical Practice
Guideline for the Management
of Candidiasis: 2016 Update by
the Infectious Diseases Society
of America. Clin Infect Dis
2015;62:e1-50.
15 Nucci M, Anaissie E. Revisiting
the Source of Candidemia:
Skin or Gut? Clin Infect Dis
2001;33:1959-67.
16 BMJ best practice. Disponible en
ligne : https://bestpractice.bmj.
com (consulté en juin 2018).
17 Akpan A, Morgan R. Oral
Candidiasis. Postgrad Med J
2002;78:455-9.
18 Laurent M, Gogly B,
Tahmasebi F, et al. Les
candidoses oropharyngées
des personnes âgées. Geriatr
Psychol Neuropsychiatr Vieil
2011;9:21-8.Millsop JW, Fazel N.
Oral candidiasis. Clin Dermatol
2016;34:487-94.
19 Millsop JW, Fazel N. Oral
candidiasis. Clin Dermatol
2016;34:487-94.
20 Williams D, Lewis M. Pathogenesis
and treatment of oral candidosis. J
Oral Microbiol 2011;3:1-11.
21 Coronado-Castellote L,
Jiménez-Soriano Y. Clinical and
microbiological diagnosis of
oral candidiasis. J Clin Exp Dent
2013;5:279-86.
22 Cuenca‐Estrella M., Verweij PE,
Arendrup MC, et al. ESCMID*
guideline for the diagnosis and
management of Candida diseases
2012: diagnostic procedures. Clin
Microbiol Infect 2012;18:9-18.
23 Rautemaa R, Ramage G. Oral
candidosis Clinical challenges of a
biofilm disease. Crit Rev Microbiol
2011;37:328-36.
24 Garcia-Cuesta C, Sarrion-
Perez M, Bagan J. Current
treatment of oral candidiasis: A
literature review. J Clin Exp Dent
2014;6:e576-82.
25 Cross LJ, Williams DW,
Sweeney CP, et al. Evaluation
of the recurrence of denture
stomatitis and Candida
colonization in a small group
of patients who received
itraconazole. Oral Surg Oral Med
Oral Pathol Oral Radiol Endod
2004;97:351-8.
26 Grimoud AM, Lodter JP, Marty N,
et al. Improved oral hygiene and
Candida species colonization level
in geriatric patients. Oral Dis
2005;11:163-9.
27 Gøtzsche PC, Johansen HK.
Nystatin prophylaxis and
treatment in severely
immunodepressed patients.
Cochrane Database Syst Rev
2014;2017.
28 Melkoumov A, Goupil M,
Louhichi F, et al. Nystatin
nanosizing enhances in vitro and
in vivo antifungal activity against
Candida albicans. J Antimicrob
Chemother 2013;68:2099-105.
29 Sklenář Z, Ščigel V, Horáčkova K,
et al. Compounded preparations
with nystatin for oral and
oromucosal administration.
Acta Pol Pharm - Drug Res
2013;70:759-62.
30 Martín MJ, Calpena AC,
Fernández F, et al. Development
of alginate microspheres as
nystatin carriers for oral mucosa
drug delivery. Carbohydr Polym
2015;117:140-9.
31 Llabot JM, Manzo RH,
Allemandi DA. Double-layered
mucoadhesive tablets containing
nystatin. AAPS PharmSciTech
2002;3.
32 Agence Fédérale de Médicaments
et des Produits de Santé (AFMPS).
Disponible en ligne : www.afmps.
be/fr (consulté en juin 2018).
33 Formulaire Thérapeutique
Magistral. 3ème édition. Disponible
en ligne : www.tmf-ftm.be/
(consulté en juin 2018).
34 Morgan R, Tsang J, Harrington N,
et al. Survey of hospital doctors’
attitudes and knowledge of oral
conditions in older patients.
Postgrad Med J 2001;77:392-4.
35 Centre belge d’information
pharmacothérapeutique (CBIP).
Disponible en ligne: www.cbip.be/
fr/start (consulté en juin 2018).
36 Hamdy RF, Zaoutis TE, Seo SK.
Antifungal stewardship
considerations for adults and
pediatrics. Virulence 2016;8:1-15.
Étude Étude
/2011;9:21-8.Mil
/
/bestpractice.bmj
/
/www.afmps
/
/